Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Caris Life Sciences (CAI) Consolidated Net Income (2024 - 2026)

Caris Life Sciences has reported Consolidated Net Income over the past 2 years, most recently at $82.0 million for Q4 2025.

  • For Q4 2025, Consolidated Net Income rose 321.82% year-over-year to $82.0 million; the TTM value through Dec 2025 reached -$2.5 million, changed N/A, while the annual FY2025 figure was -$68.1 million, 75.85% up from the prior year.
  • Consolidated Net Income for Q4 2025 was $82.0 million at Caris Life Sciences, up from $24.3 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $82.0 million in Q4 2025 and troughed at -$71.8 million in Q2 2025.